PetVivo Reports Fiscal Q2 2025 Results
14 nov. 2024 16h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and...
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2024
11 nov. 2024 10h07 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Nov. 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical...
PetVivo Engages Another Top Sales Manager, Cindy Gill, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide
21 oct. 2024 09h45 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy...
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
18 oct. 2024 09h06 HE
|
Can-Fite BioPharma Ltd.
Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M Ramat Gan, Israel, Oct. 18, 2024 (GLOBE NEWSWIRE) --...
U.S. Osteoarthritis Injectables Market Analysis 2024-2030: Rising Prevalence of Osteoarthritis & Increase in R&D Activities for Injectable Drug Developments Spurs Growth
04 oct. 2024 05h52 HE
|
Research and Markets
Dublin, Oct. 04, 2024 (GLOBE NEWSWIRE) -- The "U.S. Osteoarthritis Injectables Market Size, Share & Trends Analysis Report by Injection Type (Hyaluronic Acid Injections, Corticosteroids...
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
26 sept. 2024 08h30 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
24 sept. 2024 08h30 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
PetVivo Taps Top Sales Executive, Skylor Walker, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide
16 sept. 2024 08h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Sept. 16, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Skylor...
PetVivo’s Spryng with OsteoCushion™ Technology Featured in Visionaries on Bloomberg TV
12 sept. 2024 08h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Sept. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, was recently...
PetVivo Teams with Orthobiologic Innovations for Clincial Research and Product Commercialization
27 août 2024 08h00 HE
|
PetVivo Holdings, Inc.
Orthobiologic President & CEO, Sherman O. Canapp, Jr. and Director of Diagnositcs and Education, Debra Cannap, Join PetVivo Advisory Board MINNEAPOLIS, MN, & Annapolis Junction, MD, US,...